// App-Quantinova.ai

: Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects

Researchers

Presenter

  • Yuki Matsuzawa

Principal Investigators

  • Hirofumi Ogura

  • Takashi Nagakubo

  • Akira Wakamatsu

  • Claire Ambery

  • Bruce Miller

  • Yotaro Numachi

Medical Centers

  • Pre-Clinical Development, Development and Medical Affairs Division, GlaxoSmithKline K.K., Tokyo, Japan

  • Pre-Clinical Development, Development and Medical Affairs Division, GlaxoSmithKline K.K., Tokyo, Japan

  • Pre-Clinical Development, Development and Medical Affairs Division, GlaxoSmithKline K.K., Tokyo, Japan

  • Pharma Research & Development, Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Middlesex, United Kingdom

  • Pharma Research & Development, Respiratory Therapy Area Unit, GlaxoSmithKline, Philadelphia, United States of America

Locations

  • Japan

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Cross Over

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • NA

Study Id's

  • NCT03136380

Sponsors

  • GlaxoSmithKline Pharmaceuticals

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved